Literature DB >> 32561850

The Hippo pathway oncoprotein YAP promotes melanoma cell invasion and spontaneous metastasis.

Xiaomeng Zhang1, Lie Yang1,2, Pacman Szeto3,4, Gamze Kuser Abali3,4, Youfang Zhang3,4, Aishwarya Kulkarni1,5, Kaushalya Amarasinghe1, Jason Li1, Ismael A Vergara1,6, Ramyar Molania6, Anthony T Papenfuss1,5,6,7, Catriona McLean3, Mark Shackleton3,4, Kieran F Harvey8,9,10.   

Abstract

Melanoma is a deadly form of skin cancer that accounts for a disproportionally large proportion of cancer-related deaths in younger people. Compared with most other skin cancers, a feature of melanoma is its high metastatic capacity, although the mechanisms that confer this are not well understood. The Hippo pathway is a key regulator of organ growth and cell fate that is deregulated in many cancers. To analyse the Hippo pathway in cutaneous melanoma, we generated a transcriptional signature of melanoma cells that overexpressed YAP, the key downstream Hippo pathway oncoprotein. YAP-mediated transcriptional activity varied in melanoma cell lines but did not cluster with known genetic drivers of melanomagenesis such as BRAF and NRAS mutations. Instead, it correlated strongly with published gene expression profiles linked to melanoma cell invasiveness and varied throughout the metastatic cascade in melanoma patient tumours. Consistent with this, YAP was both necessary and sufficient for melanoma cell invasion in vitro. In vivo, YAP promoted spontaneous melanoma metastasis, whilst the growth of YAP-expressing primary tumours was impeded. Finally, we identified the YAP target genes AXL, THBS1 and CYR61 as key mediators of YAP-induced melanoma cell invasion. These data suggest that YAP is a critical regulator of melanoma metastasis.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32561850     DOI: 10.1038/s41388-020-1362-9

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  51 in total

1.  Combined vemurafenib and cobimetinib in BRAF-mutated melanoma.

Authors:  James Larkin; Paolo A Ascierto; Brigitte Dréno; Victoria Atkinson; Gabriella Liszkay; Michele Maio; Mario Mandalà; Lev Demidov; Daniil Stroyakovskiy; Luc Thomas; Luis de la Cruz-Merino; Caroline Dutriaux; Claus Garbe; Mika A Sovak; Ilsung Chang; Nicholas Choong; Stephen P Hack; Grant A McArthur; Antoni Ribas
Journal:  N Engl J Med       Date:  2014-09-29       Impact factor: 91.245

2.  Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study.

Authors:  Grant A McArthur; Paul B Chapman; Caroline Robert; James Larkin; John B Haanen; Reinhard Dummer; Antoni Ribas; David Hogg; Omid Hamid; Paolo A Ascierto; Claus Garbe; Alessandro Testori; Michele Maio; Paul Lorigan; Celeste Lebbé; Thomas Jouary; Dirk Schadendorf; Stephen J O'Day; John M Kirkwood; Alexander M Eggermont; Brigitte Dréno; Jeffrey A Sosman; Keith T Flaherty; Ming Yin; Ivor Caro; Suzanne Cheng; Kerstin Trunzer; Axel Hauschild
Journal:  Lancet Oncol       Date:  2014-02-07       Impact factor: 41.316

3.  Interchain hydrogen bonds via bound water molecules in the collagen triple helix.

Authors:  G N Ramachandran; R Chandrasekharan
Journal:  Biopolymers       Date:  1968       Impact factor: 2.505

4.  The N-terminal region of Escherichia coli lactose permease mediates membrane contact of the nascent polypeptide chain.

Authors:  U Stochaj; R Ehring
Journal:  Eur J Biochem       Date:  1987-03-16

5.  Metastatic potential of melanomas defined by specific gene expression profiles with no BRAF signature.

Authors:  Keith S Hoek; Natalie C Schlegel; Patricia Brafford; Antje Sucker; Selma Ugurel; Rajiv Kumar; Barbara L Weber; Katherine L Nathanson; David J Phillips; Meenhard Herlyn; Dirk Schadendorf; Reinhard Dummer
Journal:  Pigment Cell Res       Date:  2006-08

6.  Systematic classification of melanoma cells by phenotype-specific gene expression mapping.

Authors:  Daniel S Widmer; Phil F Cheng; Ossia M Eichhoff; Benedetta C Belloni; Marie C Zipser; Natalie C Schlegel; Delphine Javelaud; Alain Mauviel; Reinhard Dummer; Keith S Hoek
Journal:  Pigment Cell Melanoma Res       Date:  2012-03-02       Impact factor: 4.693

7.  Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study.

Authors:  James Larkin; Michele Del Vecchio; Paolo A Ascierto; Ivana Krajsova; Jacob Schachter; Bart Neyns; Enrique Espinosa; Claus Garbe; Vanna Chiarion Sileni; Helen Gogas; Wilson H Miller; Mario Mandalà; Geke A P Hospers; Ana Arance; Paola Queirolo; Axel Hauschild; Michael P Brown; Lada Mitchell; Luisa Veronese; Christian U Blank
Journal:  Lancet Oncol       Date:  2014-02-27       Impact factor: 41.316

8.  Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq.

Authors:  Itay Tirosh; Benjamin Izar; Sanjay M Prakadan; Marc H Wadsworth; Daniel Treacy; John J Trombetta; Asaf Rotem; Christopher Rodman; Christine Lian; George Murphy; Mohammad Fallahi-Sichani; Ken Dutton-Regester; Jia-Ren Lin; Ofir Cohen; Parin Shah; Diana Lu; Alex S Genshaft; Travis K Hughes; Carly G K Ziegler; Samuel W Kazer; Aleth Gaillard; Kellie E Kolb; Alexandra-Chloé Villani; Cory M Johannessen; Aleksandr Y Andreev; Eliezer M Van Allen; Monica Bertagnolli; Peter K Sorger; Ryan J Sullivan; Keith T Flaherty; Dennie T Frederick; Judit Jané-Valbuena; Charles H Yoon; Orit Rozenblatt-Rosen; Alex K Shalek; Aviv Regev; Levi A Garraway
Journal:  Science       Date:  2016-04-08       Impact factor: 47.728

9.  In vivo switching of human melanoma cells between proliferative and invasive states.

Authors:  Keith S Hoek; Ossia M Eichhoff; Natalie C Schlegel; Udo Döbbeling; Nikita Kobert; Leo Schaerer; Silvio Hemmi; Reinhard Dummer
Journal:  Cancer Res       Date:  2008-02-01       Impact factor: 12.701

10.  Decoding the regulatory landscape of melanoma reveals TEADS as regulators of the invasive cell state.

Authors:  Annelien Verfaillie; Hana Imrichova; Zeynep Kalender Atak; Michael Dewaele; Florian Rambow; Gert Hulselmans; Valerie Christiaens; Dmitry Svetlichnyy; Flavie Luciani; Laura Van den Mooter; Sofie Claerhout; Mark Fiers; Fabrice Journe; Ghanem-Elias Ghanem; Carl Herrmann; Georg Halder; Jean-Christophe Marine; Stein Aerts
Journal:  Nat Commun       Date:  2015-04-09       Impact factor: 14.919

View more
  18 in total

1.  YAP facilitates melanoma migration through regulation of actin-related protein 2/3 complex subunit 5 (ARPC5).

Authors:  Jason W Lui; Stephen P G Moore; Lee Huang; Kelsey Ogomori; Yan Li; Deborah Lang
Journal:  Pigment Cell Melanoma Res       Date:  2021-09-01       Impact factor: 4.693

2.  Inactivation of the Hippo tumor suppressor pathway promotes melanoma.

Authors:  Marc A Vittoria; Nathan Kingston; Kristyna Kotynkova; Eric Xia; Rui Hong; Lee Huang; Shayna McDonald; Andrew Tilston-Lunel; Revati Darp; Joshua D Campbell; Deborah Lang; Xiaowei Xu; Craig J Ceol; Xaralabos Varelas; Neil J Ganem
Journal:  Nat Commun       Date:  2022-06-29       Impact factor: 17.694

Review 3.  Mechanism-Centric Approaches for Biomarker Detection and Precision Therapeutics in Cancer.

Authors:  Christina Y Yu; Antonina Mitrofanova
Journal:  Front Genet       Date:  2021-08-02       Impact factor: 4.772

Review 4.  Genomic and Transcriptomic Underpinnings of Melanoma Genesis, Progression, and Metastasis.

Authors:  Olga S Cherepakhin; Zsolt B Argenyi; Ata S Moshiri
Journal:  Cancers (Basel)       Date:  2021-12-28       Impact factor: 6.639

5.  Targeting the IL-6-Yap-Snail signalling axis in synovial fibroblasts ameliorates inflammatory arthritis.

Authors:  Rebecca A Symons; Fabio Colella; Anke J Roelofs; Cosimo De Bari; Fraser L Collins; Alexandra J Rafipay; Karolina Kania; Jessica J McClure; Nathan White; Iain Cunningham; Sadaf Ashraf; Elizabeth Hay; Kevin S Mackenzie; Kenneth A Howard; Anna H K Riemen; Antonio Manzo; Susan M Clark
Journal:  Ann Rheum Dis       Date:  2021-11-29       Impact factor: 19.103

Review 6.  Targeting GPCRs and Their Signaling as a Therapeutic Option in Melanoma.

Authors:  Jérémy H Raymond; Zackie Aktary; Lionel Larue; Véronique Delmas
Journal:  Cancers (Basel)       Date:  2022-01-29       Impact factor: 6.639

7.  Dimethyl Fumarate Combined With Vemurafenib Enhances Anti-Melanoma Efficacy via Inhibiting the Hippo/YAP, NRF2-ARE, and AKT/mTOR/ERK Pathways in A375 Melanoma Cells.

Authors:  Hongxia Li; Yaping Wang; Rina Su; Yuchen Jia; Xiong Lai; Huimin Su; Yaochun Fan; Yuewu Wang; Wanjin Xing; Jianzhong Qin
Journal:  Front Oncol       Date:  2022-01-24       Impact factor: 6.244

8.  Disruption of LTBP4 Inhibition-Induced TGFβ1 Activation Promoted Cell Proliferation and Metastasis in Skin Melanoma by Inhibiting the Activation of the Hippo-YAP1 Signaling Pathway.

Authors:  Lina Wang; Dongrun Tang; Tong Wu; Fengyuan Sun
Journal:  Front Cell Dev Biol       Date:  2022-02-17

9.  Bilirubin Restrains the Anticancer Effect of Vemurafenib on BRAF-Mutant Melanoma Cells Through ERK-MNK1 Signaling.

Authors:  Yufan Tan; Xiaoyu Zhong; Xizhi Wen; Leyi Yao; Zhenlong Shao; Wenshuang Sun; Jiawen Wu; Guanmei Wen; Daolin Tang; Xiaoshi Zhang; Yuning Liao; Jinbao Liu
Journal:  Front Oncol       Date:  2021-06-18       Impact factor: 6.244

Review 10.  The Role of the Receptor Tyrosine Kinase Axl in Carcinogenesis and Development of Therapeutic Resistance: An Overview of Molecular Mechanisms and Future Applications.

Authors:  Martha Wium; Aderonke F Ajayi-Smith; Juliano D Paccez; Luiz F Zerbini
Journal:  Cancers (Basel)       Date:  2021-03-25       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.